Gilead Sciences' new drug application for sofosbuvir, an experimental drug for hepatitis C, received priority review status from the FDA. The agency is expected to issue a decision by Dec. 8.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan